Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IFN-γ positive selected T-cells
- Development stage
- Unknown
- Lead developer
- Samsung Medical Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IFN-γ positive selected T-cells are an adoptive cellular immunotherapy developed for the treatment of refractory cytomegalovirus (CMV) infections in allogeneic hematopoietic cell transplant (HCT) recipients. The process involves stimulating donor-derived T cells with the CMV-specific antigen pp65. T cells that respond by producing interferon-gamma (IFN-γ) are then isolated using a cytokine capture system (such as the CliniMACS system). These enriched, virus-specific T cells are infused into the patient to restore CMV-specific immunity and control viral replication without the need for extensive ex vivo expansion, thereby reducing the risk of graft-versus-host disease (GvHD) while providing rapid antiviral activity.
- Other names
- pp65-specific T cellspp-65-specific T cellspp 65-specific T cellsCMV-specific T-cellsdonor-derived pp65-specific T cells
02
Targets
Cytomegalovirus pp65 peptide-MHC complex
Beyond the preview
Go deeper on IFN-γ positive selected T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IFN-γ positive selected T-cells.